Onward Medical N.V. ((NL:ONWD)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Onward Medical N.V. is spearheading a pivotal clinical study titled ‘ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury.’ The study aims to evaluate the safety and effectiveness of the ARC-IM System in managing blood pressure instability in individuals with chronic spinal cord injuries, a condition that significantly impacts quality of life.
The intervention being tested is the ARC-IM System, which involves the implantation of a neurostimulator and thoracic lead to provide electrical spinal cord stimulation. This system is designed to stabilize blood pressure in affected individuals.
The study is interventional, randomized, and sham-controlled with a crossover design. It includes a triple-masking approach to ensure unbiased results. The primary goal is treatment-focused, assessing outcomes at three months post-implantation.
Key dates include the study’s start date on August 14, 2025, with primary completion expected by the end of the initial three-month phase. The last update was submitted on August 28, 2025, indicating the study is not yet recruiting.
This study could significantly impact Onward Medical’s stock performance by potentially positioning the company as a leader in innovative treatments for spinal cord injuries. The ARC-IM System could offer a competitive edge in the medical device industry, enhancing investor confidence.
The study is ongoing, with further details available on the ClinicalTrials portal.